Cargando…
Addition of metabolomics to the omics spectrum for cancer biomarker development– demonstration with the KrasG12D mouse model for pancreatic carcinoma
Autores principales: | Laiakis, Evagelia C, LaConti, Joseph J, Cheema, Amrita, Wellstein, Anton, Fornace, Albert J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075477/ http://dx.doi.org/10.1186/1471-2164-15-S2-O4 |
Ejemplares similares
-
Distinct serum metabolomics profiles associated with malignant progression in the Kras(G12D) mouse model of pancreatic ductal adenocarcinoma
por: LaConti, Joseph J, et al.
Publicado: (2015) -
Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
por: Goebel, Lisa, et al.
Publicado: (2023) -
Metabolomic Analysis in Severe Childhood Pneumonia in The Gambia, West Africa: Findings from a Pilot Study
por: Laiakis, Evagelia C., et al.
Publicado: (2010) -
Role and regulation of Yap in KrasG12D-induced lung cancer
por: Mao, Yaopan, et al.
Publicado: (2017) -
Serum Metabolomic Alterations Associated with Cesium-137 Internal Emitter Delivered in Various Dose Rates
por: Li, Heng-Hong, et al.
Publicado: (2020)